(SOURCE: UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS) – About 10 percent of lung cancers in the United States and as many as 40 percent in Asia are driven by mutations in the EGFR gene. EGFR targeted treatment advances over the previous decade now result in multiple options for controlling the disease in the body, but due to […]
(SOURCE: MAYO CLINIC) – Researchers at Mayo Clinic have identified a genetic promoter of cancer that drives a major form of lung cancer. In a new paper published this week in Cancer Cell, Mayo Clinic researchers provide genetic evidence that Ect2 drives lung adenocarcinoma tumor formation. “This paper demonstrates, for the first time, that Ect2 is required […]
(SOURCE: INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER) – Non-small cell lung cancer (NSCLC) patients with advanced disease receiving standard of care treatment have a higher overall survival (OS) than similar patients not receiving treatment. Lung cancer is the leading cause of cancer deaths worldwide, causing more deaths than breast, colon, and prostate cancers combined. NSCLC […]
(SOURCE: STANFORD UNIVERSITY MEDICAL CENTER) – A technique developed at Stanford for detecting the genetic profiles of tumor cells sifted from the bloodstream could offer a valuable tool for the clinic and the lab. Profiling the genes of lung-tumor cells from patient blood samples may be a cheap, noninvasive way to help doctors choose the right […]
(SOURCE: CEMM RESEARCH CENTER FOR MOLECULAR MEDICINE OF THE AUSTRIAN ACADEMY OF SCIENCES) – A subset of lung tumors is exquisitely sensitive to a class of recently approved anti-cancer drugs. Researchers at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna and the Ludwig Institute for Cancer Research in Oxford published […]
(SOURCE: UNIVERSITY OF MANCHESTER) A blood test could predict how well small-cell lung cancer (SCLC) patients will respond to treatment, according to new research published in Nature Medicine. Scientists, based at the Cancer Research UK Manchester Institute at The University of Manchester, isolated tumour cells that had broken away from the main cancer – known as circulating […]
(UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER) According to a recent press release, a cellular component known as the Golgi apparatus may play a role in how lung cancer metastasizes, according to researchers at The University of Texas MD Anderson Cancer Center whose findings were reported in the Nov. 21 online issue of the Journal […]
(UNIVERSITY OF ILLINOIS AT CHICAGO) According to a recent press release, researchers at the University of Illinois at Chicago have identified a new way to block the action of genetic mutations found in nearly 30 percent of all cancers.
(TUFTS UNIVERSITY, HEALTH SCIENCES CAMPUS) According to a recent press release, beta-cryptoxanthin (BCX), a carotenoid pigment compound found primarily in plants, reduces the number and invasiveness of tumors in mouse and cell models of lung cancer, report scientists from the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University (USDA HNRCA). The […]
(Medical Daily) According to an article recently published in Medical Daily, researchers presented results from their phase three clinical trial at the European Society for Medical Oncology congress. Using an experimental synthesized antibody treatment that triggers the immune system into attacking tumor cells, proved to be a clear winner over conventional chemotherapy for patients with advanced non-small-cell lung […]
(PR Newswire) Boehringer Ingelheim and Sarah Cannon Research Institute recently announced a new strategic collaboration. This partnership brings together Boehringer Ingelheim’s extensive experience in cancer drug development and Sarah Cannon’s expertise and leadership in designing and optimizing clinical trials. The partnership will help bring innovative cancer treatments to patients with unmet medical needs.
(PR Newswire) According to a recent press release, IBA, the worldwide leading expert in proton therapy announced that 50,000 patients have been treated by clinical partners using IBA’s leading edge technology. With over half of the proton therapy centers worldwide and counting. IBA proton therapy treats more patients than all other proton therapy vendors combined. […]